CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Mantle Cell Lymphoma.

New electronic cigarette products may couple nicotine addiction with gaming disorder

In an “Industry Watch” research paper in the journal Tobacco Control, two scientists at the University of California, Riverside, raise the alarm on new electronic

July 20, 2024

AI-designed drug ISM5939 granted IND clearance for cancer clinical trials

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential

November 22, 2024

CAR NK therapy looks durable in a small trial, giving insight into large Takeda study

An “off-the-shelf” cell therapy engineered using natural killer cells resulted in lasting responses in a small clinical trial for certain lymphomas and leukemia, according to

January 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.